Header Logo

Connection

GEORGE HUTTON to Multiple Sclerosis

Back to Details
This is a "connection" page, showing publications GEORGE HUTTON has written about Multiple Sclerosis.
GEORGE HUTTON
Connection Strength
5.124
Multiple Sclerosis
  1. Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis: A Clinical Update. Neurol Clin. 2023 02; 41(1):87-106.
    View in: PubMed
    Score: 0.590
  2. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021 Aug; 53:103072.
    View in: PubMed
    Score: 0.536
  3. The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021 May; 50:102877.
    View in: PubMed
    Score: 0.526
  4. Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016 Oct 15; 369:51-52.
    View in: PubMed
    Score: 0.381
  5. Regulatory effects of interferon-? on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010 Oct; 30(10):751-7.
    View in: PubMed
    Score: 0.256
  6. Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025 Dec; 104:106750.
    View in: PubMed
    Score: 0.180
  7. Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021. Mult Scler. 2025 Nov; 31(13):1595-1599.
    View in: PubMed
    Score: 0.180
  8. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005; 56:273-302.
    View in: PubMed
    Score: 0.172
  9. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.170
  10. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
    View in: PubMed
    Score: 0.170
  11. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.168
  12. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
    View in: PubMed
    Score: 0.153
  13. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
    View in: PubMed
    Score: 0.144
  14. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
    View in: PubMed
    Score: 0.141
  15. Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Mult Scler Relat Disord. 2022 Feb; 58:103498.
    View in: PubMed
    Score: 0.139
  16. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
    View in: PubMed
    Score: 0.137
  17. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Sep; 54:103149.
    View in: PubMed
    Score: 0.135
  18. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
    View in: PubMed
    Score: 0.132
  19. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
    View in: PubMed
    Score: 0.125
  20. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
    View in: PubMed
    Score: 0.125
  21. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020 Dec; 16(12):1670-1676.
    View in: PubMed
    Score: 0.123
  22. Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020 Jan; 59(1):13-20.
    View in: PubMed
    Score: 0.119
  23. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011 Aug 02; 77(5):505-7.
    View in: PubMed
    Score: 0.068
  24. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain. 2008 Feb; 131(Pt 2):e89; author reply e90.
    View in: PubMed
    Score: 0.052
  25. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S3-11.
    View in: PubMed
    Score: 0.043
  26. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39.
    View in: PubMed
    Score: 0.041
  27. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
    View in: PubMed
    Score: 0.041
  28. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008.
    View in: PubMed
    Score: 0.040
  29. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002 Dec; 24(12):1998-2021.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.